A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

Bernstein Clinical Research Center

Overview

Management of animal induced occupational asthma is mainly avoidance, but this is not feasible for many occupations. Treatment with avoidance and conventional treatment is also not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and may be effective at reducing symptoms and disease progression in the animal handlers population.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Allergy Induced Asthma

Interventions

omalizumabDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. ages 18-65 2. occupation that involves close contact with animals 3. stable dose of ICS for 30 days 4. Skin test positive to one or more animals 5. evidence of asthma on spirometry 6. demonstrate PEFR variability- Exclusion Criteria: 1. on allergen immunotherapy 2. on prohibited medications 3. unstable asthma 4. recent URI 5. known hypersensitivity to omalizumab-

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.